TXA709

TXA709 is an orally administered **small-molecule antibacterial prodrug** developed by TAXIS Pharmaceuticals for treatment of serious *Staphylococcus aureus* infections, especially methicillin-resistant *S. aureus* infections. It is converted in serum to the active agent TXA707 and acts by targeting **filamenting temperature-sensitive mutant Z**, a bacterial cell-division protein required for cytokinesis. TXA709 has been positioned as a novel anti-resistance agent for use alone or in combination with older beta-lactam and other generic antibiotics whose utility has been reduced by resistance, with reported preclinical activity against MRSA, vancomycin-intermediate *S. aureus*, vancomycin-resistant *S. aureus*, and linezolid-resistant *S. aureus*. Publicly described development indicates completion of Phase I testing and FDA Qualified Infectious Disease Product designation.